التفاصيل البيبلوغرافية
| العنوان: |
Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis. |
| المؤلفون: |
Strauss, Timmy, Günther, Claudia, Schnabel, Anja, Wolf, Christine, Hahn, Gabriele, Lee-Kirsch, Min Ae, Brück, Normi |
| المصدر: |
Pediatric Rheumatology; 9/19/2023, Vol. 21 Issue 1, p1-5, 5p |
| مصطلحات موضوعية: |
MYOSITIS, DERMATOMYOSITIS, RESPONSE inhibition, MUSCLE weakness, INTERSTITIAL lung diseases, INTRAVENOUS immunoglobulins, LUNG diseases |
| مستخلص: |
Background: Juvenile dermatomyositis (jDM) is the most common idiopathic inflammatory myopathy of childhood. Amyopathic or hypomyopathic courses have been described. Case presentation: We present the case of a 4-year-old patient with MDA5 antibody positive jDM and interstitial lung disease. In our patient, typical symptoms of jDM with classical skin lesions, arthritis, proximal muscle weakness, and ulcerative calcifications were observed. Due to the severity of the disease and the pulmonary changes, therapy with the Janus kinase (JAK) inhibitor ruxolitinib was added to the therapy with corticosteroids, intravenous immunoglobulins (IVIG) and hydroxychloroquine leading to a fast and sustained remission. Conclusion: While there is growing evidence that JAK inhibition is a promising therapeutic option in jDM our case report shows that this approach may also be effective in MDA5-positive jDM with high risk features. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pediatric Rheumatology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder